BACKGROUND: The activation of NAD+-dependent deacetylase, Sirt1, by the administration of nicotinamide mononucleotide (NMN) ameliorates various aging-related diseases. METHODS: Diabetic db/db mice were treated with NMN transiently for 2 weeks and observed for effects on diabetic nephropathy (DN). RESULTS: At 14 weeks after the treatment period, NMN attenuated the increases in urinary albumin excretion in db/db mice without ameliorating hemoglobin A1c levels. Short-term NMN treatment mitigated mesangium expansion and foot process effacement, while ameliorating decreased Sirt1 expression and increased claudin-1 expression in the kidneys of db/db mice. This treatment also improved the decrease in the expression of H3K9me2 and DNMT1. Short-term NMN treatment also increased kidney concentrations of NAD+ and the expression of Sirt1 and nicotinamide phosphoribosyltransferase (Nampt), and it maintained nicotinamide mononucleotide adenyltransferase1 (Nmnat1) expression in the kidneys. In addition, survival rates improved after NMN treatment. CONCLUSIONS: Short-term NMN treatment in early-stage DN has remote renal protective effects through the upregulation of Sirt1 and activation of the NAD+ salvage pathway, both of which indicate NMN legacy effects on DN.
BACKGROUND: The activation of NAD+-dependent deacetylase, Sirt1, by the administration of nicotinamide mononucleotide (NMN) ameliorates various aging-related diseases. METHODS: Diabetic db/db mice were treated with NMN transiently for 2 weeks and observed for effects on diabetic nephropathy (DN). RESULTS: At 14 weeks after the treatment period, NMN attenuated the increases in urinary albumin excretion in db/db mice without ameliorating hemoglobin A1c levels. Short-term NMN treatment mitigated mesangium expansion and foot process effacement, while ameliorating decreased Sirt1 expression and increased claudin-1 expression in the kidneys of db/db mice. This treatment also improved the decrease in the expression of H3K9me2 and DNMT1. Short-term NMN treatment also increased kidney concentrations of NAD+ and the expression of Sirt1 and nicotinamide phosphoribosyltransferase (Nampt), and it maintained nicotinamide mononucleotide adenyltransferase1 (Nmnat1) expression in the kidneys. In addition, survival rates improved after NMN treatment. CONCLUSIONS: Short-term NMN treatment in early-stage DN has remote renal protective effects through the upregulation of Sirt1 and activation of the NAD+ salvage pathway, both of which indicate NMN legacy effects on DN.
Authors: Juliana Camacho-Pereira; Mariana G Tarragó; Claudia C S Chini; Veronica Nin; Carlos Escande; Gina M Warner; Amrutesh S Puranik; Renee A Schoon; Joel M Reid; Antonio Galina; Eduardo N Chini Journal: Cell Metab Date: 2016-06-14 Impact factor: 27.287
Authors: Maryam Afkarian; Leila R Zelnick; Yoshio N Hall; Patrick J Heagerty; Katherine Tuttle; Noel S Weiss; Ian H de Boer Journal: JAMA Date: 2016-08-09 Impact factor: 56.272
Authors: Quan Hong; Lu Zhang; Bhaskar Das; Zhengzhe Li; Bohan Liu; Guangyan Cai; Xiangmei Chen; Peter Y Chuang; John Cijiang He; Kyung Lee Journal: Kidney Int Date: 2018-02-22 Impact factor: 10.612
Authors: Ali Poyan Mehr; Mei T Tran; Kenneth M Ralto; David E Leaf; Vaughan Washco; Joseph Messmer; Adam Lerner; Ajay Kher; Steven H Kim; Charbel C Khoury; Shoshana J Herzig; Mary E Trovato; Noemie Simon-Tillaux; Matthew R Lynch; Ravi I Thadhani; Clary B Clish; Kamal R Khabbaz; Eugene P Rhee; Sushrut S Waikar; Anders H Berg; Samir M Parikh Journal: Nat Med Date: 2018-08-20 Impact factor: 53.440
Authors: Eija Pirinen; Carles Cantó; Young Suk Jo; Laia Morato; Hongbo Zhang; Keir J Menzies; Evan G Williams; Laurent Mouchiroud; Norman Moullan; Carolina Hagberg; Wei Li; Silvie Timmers; Ralph Imhof; Jef Verbeek; Aurora Pujol; Barbara van Loon; Carlo Viscomi; Massimo Zeviani; Patrick Schrauwen; Anthony A Sauve; Kristina Schoonjans; Johan Auwerx Journal: Cell Metab Date: 2014-05-08 Impact factor: 27.287
Authors: Bernardo Rodriguez-Iturbe; Richard J Johnson; Miguel A Lanaspa; Takahiko Nakagawa; Fernando E Garcia-Arroyo; Laura G Sánchez-Lozada Journal: Am J Physiol Regul Integr Comp Physiol Date: 2022-03-10 Impact factor: 3.619